Physiogenex
Physiogenex is a preclinical CRO specializing in animal models and services for metabolic disorders such as obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, and cardiovascular complications. With over 15 years of experience, they develop in-house and benchmarked preclinical models, offering a wide range of in vivo, ex vivo, and in vitro services, including pharmacology research, biomarker analysis, histology, and consulting. Their mission is to support drug development in metabolic diseases through high-quality, reliable preclinical studies and innovative models, aiming to accelerate the path to clinical success.
Industries
Nr. of Employees
small (1-50)
Physiogenex
Services
On-site contract execution of efficacy studies in validated small-animal models to evaluate glucose, lipid and cardiac metabolism endpoints, plus molecular imaging and radiotracer analyses.
Medium-throughput in vitro and ex vivo assays using human and rodent adipocytes, muscle preparations and hepatocyte/3D spheroid systems to assess glucose uptake, lipolysis and steatosis-related endpoints.
Analytical services including colorimetric assays, lipid profiling, ELISA/multiplex panels, qPCR, protein analysis and comprehensive histology/IHC with blinded scoring for liver and kidney pathologies.
Combined in vivo and ex vivo workflows to characterize innate and adaptive immune responses in metabolic tissues using FACS and complementary biochemical and histological endpoints.
Rapid and diet-induced preclinical NASH/MASH and liver fibrosis models, plus fibrosis models for kidney and lung, with standardized biomarkers, histology and blinded NAFLD activity scoring.
Preclinical dyslipidaemia and atherosclerosis models with radiotracer-based lipoprotein kinetics, reverse cholesterol transport assays, lipoprotein profiling and vascular inflammation imaging.
On-site contract execution of efficacy studies in validated small-animal models to evaluate glucose, lipid and cardiac metabolism endpoints, plus molecular imaging and radiotracer analyses.
Medium-throughput in vitro and ex vivo assays using human and rodent adipocytes, muscle preparations and hepatocyte/3D spheroid systems to assess glucose uptake, lipolysis and steatosis-related endpoints.
Analytical services including colorimetric assays, lipid profiling, ELISA/multiplex panels, qPCR, protein analysis and comprehensive histology/IHC with blinded scoring for liver and kidney pathologies.
Combined in vivo and ex vivo workflows to characterize innate and adaptive immune responses in metabolic tissues using FACS and complementary biochemical and histological endpoints.
Rapid and diet-induced preclinical NASH/MASH and liver fibrosis models, plus fibrosis models for kidney and lung, with standardized biomarkers, histology and blinded NAFLD activity scoring.
Preclinical dyslipidaemia and atherosclerosis models with radiotracer-based lipoprotein kinetics, reverse cholesterol transport assays, lipoprotein profiling and vascular inflammation imaging.
Expertise Areas
- Preclinical pharmacology for cardiometabolic diseases
- Metabolic disease model development (obesity, diabetes, NASH/MASH, fibrosis)
- Preclinical immunometabolism and inflammation studies
- Dyslipidaemia and atherosclerosis preclinical evaluation
Key Technologies
- Radioisotope tracer assays for metabolic flux
- Euglycemic hyperinsulinemic and hyperglycemic clamps
- 14C-2-deoxyglucose tissue uptake assays
- Flow cytometry / FACS immunophenotyping
News & Updates
Physiogenex delivers its novel rat model of IgA nephropathy (IgAN) to evaluate drug efficacy rapidly, presented at ASN Kidney Week 2024.
Presentation of effects of a novel FXR agonist in hamster models of ALD/MetALD at APASL 2024.
HepaRegenix demonstrates benefits of first-in-class MKK4 inhibitors in a mouse model of liver fibrosis.
Presentation of a novel obese NASH hamster model at the London Congress, highlighting its relevance for drug testing.
Physiogenex now delivers its novel rat model of IgA nephropathy (IgAN) to evaluate the efficacy of drugs targeting IgAN, in only 8 days! The model has been presented at the ASN Kidney Week 2024.
Presentation of effects of a novel FXR agonist in hamster models of ALD/MetALD at APASL 2024.
Physiogenex delivers its novel rat model of IgA nephropathy (IgAN) to evaluate drug efficacy rapidly, presented at ASN Kidney Week 2024.
Presentation of effects of a novel FXR agonist in hamster models of ALD/MetALD at APASL 2024.
HepaRegenix demonstrates benefits of first-in-class MKK4 inhibitors in a mouse model of liver fibrosis.
Presentation of a novel obese NASH hamster model at the London Congress, highlighting its relevance for drug testing.
Physiogenex now delivers its novel rat model of IgA nephropathy (IgAN) to evaluate the efficacy of drugs targeting IgAN, in only 8 days! The model has been presented at the ASN Kidney Week 2024.
Presentation of effects of a novel FXR agonist in hamster models of ALD/MetALD at APASL 2024.